Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

7 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Discontinuation of BRAF/MEK-Directed Targeted Therapy after Complete Remission of Metastatic Melanoma-A Retrospective Multicenter ADOReg Study.
Stege H, Haist M, Schultheis M, Fleischer MI, Mohr P, Meier F, Schadendorf D, Ugurel S, Livingstone E, Zimmer L, Herbst R, Pföhler C, Kähler K, Weichenthal M, Terheyden P, Nashan D, Debus D, Kaatz M, Ziller F, Haferkamp S, Forschner A, Leiter U, Kreuter A, Ulrich J, Kleemann J, Bradfisch F, Grabbe S, Loquai C. Stege H, et al. Among authors: fleischer mi. Cancers (Basel). 2021 May 12;13(10):2312. doi: 10.3390/cancers13102312. Cancers (Basel). 2021. PMID: 34065877 Free PMC article.
Anticoagulation with Factor Xa Inhibitors Is Associated with Improved Overall Response and Progression-Free Survival in Patients with Metastatic Malignant Melanoma Receiving Immune Checkpoint Inhibitors-A Retrospective, Real-World Cohort Study.
Haist M, Stege H, Pemler S, Heinz J, Fleischer MI, Graf C, Ruf W, Loquai C, Grabbe S. Haist M, et al. Among authors: fleischer mi. Cancers (Basel). 2021 Oct 12;13(20):5103. doi: 10.3390/cancers13205103. Cancers (Basel). 2021. PMID: 34680252 Free PMC article.
Response durability after cessation of immune checkpoint inhibitors in patients with metastatic Merkel cell carcinoma: a retrospective multicenter DeCOG study.
Stege HM, Haist M, Schultheis S, Fleischer MI, Mohr P, Ugurel S, Terheyden P, Thiem A, Kiecker F, Leiter U, Becker JC, Meissner M, Kleeman J, Pföhler C, Hassel J, Grabbe S, Loquai C. Stege HM, et al. Among authors: fleischer mi. Cancer Immunol Immunother. 2021 Nov;70(11):3313-3322. doi: 10.1007/s00262-021-02925-4. Epub 2021 Apr 18. Cancer Immunol Immunother. 2021. PMID: 33870464 Free PMC article.
Outcome of melanoma patients with elevated LDH treated with first-line targeted therapy or PD-1-based immune checkpoint inhibition.
Knispel S, Gassenmaier M, Menzies AM, Loquai C, Johnson DB, Franklin C, Gutzmer R, Hassel JC, Weishaupt C, Eigentler T, Schilling B, Schummer P, Sirokay J, Kiecker F, Owen CN, Fleischer MI, Cann C, Kähler KC, Mohr P, Bluhm L, Niebel D, Thoms KM, Goldinger SM, Reinhardt L, Meier F, Berking C, Reinhard R, Susok L, Ascierto PA, Drexler K, Pföhler C, Tietze J, Heinzerling L, Livingstone E, Ugurel S, Long GV, Stang A, Schadendorf D, Zimmer L. Knispel S, et al. Among authors: fleischer mi. Eur J Cancer. 2021 May;148:61-75. doi: 10.1016/j.ejca.2021.01.034. Epub 2021 Mar 15. Eur J Cancer. 2021. PMID: 33735811